Kornimate/medical-research-clean huggingface dataset:
probiotics as a prophylaxis to prevent clinical manifestations of oral candidosis in patients with sjogren's syndrome

Conditions: Sjogren's Syndrome

Summary: sjogren's syndrome is an autoimmune chronic disease. it has two forms primary sjogren's syndrome charactrized by dry eyes and dry mouth. secondary sjogren's syndrome characterized by rheumatoid diseases as rheumatoid arthritis, scleroderma and lupus erythematosus. ss patients are most liable to oral candidiasis , so they need prophylaxis aganist oral candidiasis. probiotic bacteria are live microorganisms that when administered in adequate amounts confer benefits to health.probiotics are commonly used as a prophylaxis aganist oral candidosis.


Eligibility criteria:
inclusion criteria: * primary or scondary sjogren's syndrome exclusion criteria: * allergy to milk derivatives previous intake of antifungals
the effect of synbiotics supplement on lipid profile, liver enzymes, inflammatory factors and hepatic fibrosis in lean and normal weight patients with nonalcoholic fatty liver

Conditions: Non Alcoholic Steatohepatitis

Summary: introduction: currently, nonalcoholic fatty liver disease (nafld) is the most common liver disease in the world. the only approved treatment for it is lifestyle modification and weight loss; however, there is no evidence for patients with normal or low body mass index (bmi). the aim of this study is to evaluate the efficacy of symbiotic supplementation in nafld patients with normal or low bmi. methods and analysis: in this randomized, double-blind, placebo-controlled clinical trial protocol, 21 cases and 21 controls will be individually matched based on age and sex. this 42 patients with nafld will be supplemented twice daily for 28 wk with either a synbiotic or a placebo capsule. both groups will be advised to follow an energy balanced diet and physical activity recommendations.


Eligibility criteria:
inclusion criteria: * age of 18 to 70 years * body mass index (bmi) below 25 * serum alaninaminotransferase more than 1.5 fold of upper limit of normal range * sonographic findings compatible with hepatic steatosis (degree 2 or more) exclusion criteria: * diabetes * taking any kind of antibiotics two weeks before recruitment * history of alcohol consumption * pregnancy or lactation * professional athletes * other liver disease (viral/etc) * use of drugs such as calcium channel blockers, high dose synthetic estrogens, methotrexate , amiodarone, steroids, chloroquine, immunosuppressive drugs, lipid-lowering agents, metformin and vitamin e * a history of hypertension, cardiovascular disease, pulmonary disease, renal disease \& celiac disease; cirrhosis * history of upper gi surgery / prior surgical procedures such as jejunoileal or jejunocolic bypass, gastroplasty * following program to lose weight in recent 3 mo * a history of hypothyroidism or cushing's syndrome
training cognitive control processes in older adults

Conditions: Neurologic Manifestations; Neurobehavioral Manifestations

Summary: control processes are classes of brain activity that initiate, coordinate, synchronize, and regulate elemental cognitive functions for the conduct of goal-directed behavior. the proposed research investigates whether exposure to a computer-based training protocol designed to enhance cognitive control processes will improve cognitive performance in healthy older adults.

the proposed research investigates whether exposure to a computer-based training protocol designed to enhance cognitive control processes will improve cognitive performance in healthy older adults. cognitively normal adults aged 60-75 will be randomized into three experimental groups: 1) video game play with training strategy; 2) video game play without training strategy (active control); 3) minimal contact (passive control). subjects in groups 1 and 2 will be instructed to play the complex, high-demand video game, space fortress, for 36 one-hour sessions over 12 weeks. subjects in group 3 will receive all assessments but will not play the computer game.

Eligibility criteria:
inclusion criteria: * age 60-75 * willingness to adhere to training protocol * adequate english proficiency exclusion criteria: * known history of cognitive impairment, dementia, stroke, seizure disorder, or other neuropsychiatric condition judged to impact cognitive performance * taking medications known to influence cognitive performance * sensory (e.g. visual, auditory) or physical (e.g. severe arthritic, orthopedic, neurologic) impairment incompatible with use of a standard computer workstation. * enrolled in a concurrent study that could affect the outcome of this study

Keywords: cognition cognition disorders executive function cognitive control attentional control biomedical enhancement cognitive enhancement computerized computer-based video game
a single intraarticular injection of prp for early knee oa

Conditions: Knee Osteoarthritis

Summary: this study aimed to investigate the efficacy of a single intraarticular injection of prp for the treatment of early knee oa.

platelet-rich plasma (prp) has been reported to be effective for the treatment of knee osteoarthritis (oa). this study aimed to investigate the efficacy of a single intraarticular injection of prp for the treatment of early knee oa. in a prospective trial with 6-month follow-up, patients with early knee oa were recruited and received a single intraarticular prp injection. several outcomes were measured.

Eligibility criteria:
inclusion criteria: * aged 20-70 years * symptomatic knee oa with pain for at least 6 months despite conservative treatment such as analgesics, nsaids and/or physical therapy * average knee pain of at least 30 mm on a 100-mm visual analog (vas) scale * grade 1 or 2 knee oa according to the kellgren-lawrence grading system based on -radiographs taken within the previous 6 months * radiological evidence of bilateral knee oa was accepted if global pain vas in the contralateral knee was less than 30 mm. exclusion criteria: * previous orthopedic surgery on the spine or lower limbs * disabling oa of either hip or foot * knee instability or marked valgus/varus deformity * history of severe knee trauma; intraarticular injections into the knee in the past 6 months * infections or skin diseases around the target knee * women ascertained or suspected pregnancy or lactating * presence of malignancy, hematological disease, collagen vascular diseases, or autoimmune diseases; * therapy with anticoagulants or anti-aggregating agent * serious medical conditions that would interfere with the assessments during the study.

Keywords: knee osteoarthritis platelet rich plasma
study to explore the onset of efficacy on magnetic resonance disease activity of bg00012 (dimethyl fumarate) in patients with relapsing remitting multiple sclerosis

Conditions: Relapsing Remitting Multiple Sclerosis

Summary: the primary objective of the study is to assess the early efficacy of treatment with bg00012 (dimethyl fumarate) 240 mg twice daily (bid) in the brain of newly diagnosed and naive-to-treatment patients with relapsing-remitting multiple sclerosis (rrms). the secondary objectives are to establish the time course of the beneficial effect of bg00012 240 mg bid over 24 weeks and to evaluate the safety of bg00012.


Eligibility criteria:
key inclusion criteria: * participants with rrms (mcdonald criteria, 2010) who do not accept current injectable firstline dmts. * multiple sclerosis (ms) onset within one year before enrolment * ≥ 1 gd+ lesions at a brain mri scan performed within three months beforeenrolment. * no previous disease modifying and/or immunosuppressive treatments for ms. * must have a baseline edss between 0.0 and 5.0, inclusive. · women of childbearing potential (i.e. who are not post-menopausal for at least 1 year) and men must practice effective contraception (as defined by the investigator) during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment. exclusion criteria: * primary progressive, secondary progressive, or progressive relapsing ms, as defined by lublin and reingold (lublin and reingold 1996) * previous disease modifying and/or immunosuppressive treatments for ms, including tcell or t-cell receptor vaccination, any therapeutic monoclonal antibody, mitoxantrone, cyclophosphamide * previous treatment with fumaderm®, dimethyl fumarate or other fumarates * history of malignancy (except basal cell carcinoma that has been completely excised prior to study enrollment) * history of severe allergic or anaphylactic reactions or known drug hypersensitivity.known allergy/hypersensitivity to gadolinium. * history of abnormal laboratory results indicative of any significant endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, renal, and/or other major disease that in the opinion of the investigator would preclude participation in a clinical trial. * history of or positive test result at screening for human immunodeficiency virus (hiv).positive for hepatitis c antibody and/or positive for hepatitis b surface antigen (hbsag) at screening. * history of drug or alcohol abuse (as defined by the investigator) within the 2 years prior to inclusion. * an ms relapse that has occurred within the 30 days prior to inclusion (screening) and/or the subject has not stabilized from a previous relapse prior to inclusion. note: other protocol-defined inclusion/exclusion criteria may apply.

Keywords: relapsing remitting multiple sclerosis
efficacy of fuzheng tongfu jiedu prescription for treating gastrointestinal dysfunction associated with sepsis

Conditions: Sepsis Abdominal; Gastrointestinal Dysfunction; Traditional Chinese Medicine

Summary: this study is a single-center, randomized, double-blind, placebo-controlled trial.

the study is designed to evaluate efficacy and safety of fztfjd for treating gastrointestinal dysfunction associated with sepsis compared to placebo in combination with conventional western medicine treatment. participants included in this study are diagnosed with sepsis-induced gastrointestinal dysfunction classified as acute gastrointestinal injury (agi)grades i-iii. a total of seventy patients will be randomly assigned in a 1:1 ratio to receive either fztfjd or placebo. the study encompasses a treatment duration of seven days followed by a twenty-one-day safety follow-up period. the agi grade as the primary outcome measure will be assessed, while gut symptom score, abdominal pressure and circumference, sofa and apache ii scores, inflammation level as well as intestinal barrier function will serve as secondary outcome measures. additionally, length of icu stay and 28-day mortality will be included as prognostic indicators in this study.

Eligibility criteria:
inclusion criteria: 1. clinical diagnosis of sepsis-induced gastrointestinal dysfunction with acute agi grade i-iii. 2. 50-90 years old, regardless of gender. 3. sequential organ failure assessment (sofa) score ≥ 2. 4. diagnosed with sepsis-induced gastrointestinal dysfunction within 24 hours. 5. voluntary participation with signed informed consent. exclusion criteria: 1. icu length of stay ≤ 3 days (due to death, discharge, or transfer), rendering gastrointestinal function evaluation unfeasible. 2. patients with allergies or allergic constitution to the investigational herbal medications. 3. inability to measure intra-abdominal pressure or abdominal circumference due to obesity (weight \> 150 kg), trauma, or surgical factors. 4. severe organic diseases: lower gastrointestinal bleeding, malignancies, cirrhosis, chronic renal failure (uremic stage), hematologic disorders, hiv, etc. 5. history of gastrointestinal surgery. 6. long-term use of corticosteroids or immunosuppressants. 7. severe psychiatric disorders or inability to cooperate with trial protocols. 8. participation in other clinical trials within 30 days. 9. pregnant or lactating women. 10. participated in other clinical studies in the past 3 months.

Keywords: gastrointestinal dysfunction sepsis traditional chinese medicine fuzheng tongfu jiedu decoction
effects of hallux valgus deformity on rear foot position, pain, function, and quality of life in women

Conditions: Hallux Valgus; Pain

Summary: to investigate relationship between hv deformity and position of rearfoot joints, and its effects on the quality of life, pain, and related functional status in women with bilateral hallux valgus (hv).

to investigate relationship between hv deformity and position of rearfoot joints, and its effects on the quality of life, pain, and related functional status in women with bilateral hallux valgus (hv). study included 27 right-dominant women. demographic data, hv angle, weight-bearing and non-weight-bearing subtalar pronation (sp), and navicular height were recorded. visual analog scale, foot function index (ffi), and the american orthopaedic foot and ankle society (aofas) mtp-ip along with aofas mid foot (mf) scales, and sf-36 were used. hv angle, weight-bearing sp, and pain intensity of the left foot were higher. hv angle of left foot was correlated with all sub-sections of ffi, pain parameter of aofas mtp-ip, and pain and total score of aofas-mf scale ). hv angle of left foot was correlated with physical role, pain, and social function sub-domains of sf-36. right hv angles were correlated with right foot pain and non-weight-bearing sp.increasing hv angle and pathomechanical changes in rear foot were correlated. besides, although all participants were right-dominant, their left foot problems were more highlighted.

Eligibility criteria:
inclusion criteria:inclusion criteria were as follows: * women in an age range of 18-55 years, * having bilateral deformity with right-dominance, * first mtp angle of \> 15° as radiologically determined by the referring physician, * deformity intensity \> 2 based on the manchester scale, * muscle forces on ankle and foot \> 4 * having no systemic disease that affects foot biomechanics with no history of surgery, * having no neurological problems, * having no cognitive, mental, or psychological problems. exclusion criteria: -

Keywords: hallux valgus pain functional status quality of life
art-2 pilot - driving pressure limited ventilation for patients with ards

Conditions: Acute Respiratory Distress Syndrome

Summary: this is a multicenter randomized controlled pilot trial to investigate the feasibility of a driving pressure limited mechanical ventilation strategy compared to the ards clinical network strategy (conventional strategy) in patients with acute respiratory distress syndrome (ards).

mechanical ventilation has the potential to produce or worsen alveolar injury. driving pressure is the difference between plateau pressure and peep. evidence from observational studies suggests that elevated driving pressure is the main independent determinant of ventilator-induced lung injury, however clinical trials are needed to establish whether targeting low driving pressures can improve clinical outcomes in patients with acute respiratory distress syndrome (ards). thus, art2pilot is a multicenter randomized controlled trial to assess the feasibility of a driving pressure limited mechanical ventilation strategy compared to the ards clinical network strategy (conventional strategy) in patients with ards. patients considered to this trial are those in mechanical ventilation with diagnosis of ards of less than 72 hours duration. we will exclude patients with less than 18 years old; contraindication to hypercapnia such as intracranial hypertension or recent acute coronary syndrome; patients in which a high probability of death within 24 hours is anticipated and patients under exclusive palliative care. eligible patients will be randomized to the driving pressure limited ventilation strategy or ardsnet strategy. the primary outcome is driving pressure between days 1 and 3.

Eligibility criteria:
inclusion criteria: * patients on invasive mechanical ventilation with diagnosis of ards of less than 72 hours duration. exclusion criteria: * less than 18 years old. * presence of any contraindication to hypercapnia as suspected or confirmed intracranial hypertension or recent (\<7 days) acute coronary syndrome. * patients in which a high probability of death within 24 hours is anticipated. * patients under exclusive palliative care.
early weightbearing and mobilization versus non-weightbearing and mobilization in unstable ankle fractures

Conditions: Ankle Injuries

Summary: the primary objective of the investigators randomized controlled trial is to determine if early protected weightbearing and ankle range of motion after surgical treatment (open reduction internal fixation - orif) for ankle fractures improves the rate of return to work and functional outcome compared to postoperative ankle immobilization in a non-weightbearing cast.

this is a randomized controlled trial comparing early weightbearing and mobilization vs immobilization and non-weightbearing after initial treatment of unstable ankle fractures. the primary objective of our randomized control trial is to determine if early protected weightbearing and ankle range of motion post open reduction internal fixation (orif) for unstable ankle fractures improves the rate of return to work and functional outcome compared to postoperative ankle immobilization in a non-weightbearing cast. our secondary objective is to determine the rate of adverse events (wound healing, infection, hardware failure) with early weightbearing and rom comparable to rates with traditional post-op ankle immobilization.

Eligibility criteria:
inclusion criteria: * unilateral unstable ankle fracture requiring surgical stabilization * treatment within two weeks of injury * closed or low grade open ankle fracture (grade 1 and/or 2) * skeletally mature exclusion criteria: * skeletally immature * previous ipsilateral ankle surgery * bilateral ankle fractures or other major injuries that would affect recovery time * grade 3 open fractures * inability to co-operate with post-op protocol (advanced dementia, polytrauma patient) * non-ambulatory pre injury * tibial plafond fractures including articular impaction requiring elevation * syndesmosis injury requiring fixation * posterior malleolus fracture - more than 25% of articular surface

Keywords: ankle fracture return to work return to function rehabilitation weight-bearing
computed tomography for early detection of cancer in women who are at risk for lung cancer

Conditions: Lung Cancer

Summary: rationale: imaging procedures such as computed tomography may improve the ability to detect lung cancer earlier. purpose: screening and diagnostic study of computed tomography in women who are at risk for lung cancer.

objectives: * determine the ability of computed tomography (ct) to detect early lung parenchymal abnormalities in women at high risk for lung cancer. * determine the number of abnormal findings detected by ct that develop into lung cancer in these patients. * correlate these abnormalities with the presence of k-ras and p53 mutations in the sputum and bronchoalveolar lavage in these patients. * develop and implement appropriate educational materials regarding lung cancer in women and provide referrals to other programs, such as smoking cessation programs. outline: patients complete a questionnaire at baseline to assess demographics, medical history, smoking history, menopausal status, estrogen therapy, and diet. patients then undergo a low-dose computed tomography (ct) scan without contrast. patients with normal ct results undergo additional ct scans every 12 months. patients with abnormal ct results undergo a diagnostic ct scan (in the absence of prior studies). patients with indeterminate nodules (less than 5 mm in size) undergo surveillance ct studies within 3-4 months. if nodules remain unchanged in size, patients undergo additional surveillance ct studies at 6 months and 1 year. patients with lung parenchymal abnormalities on ct suspicious for malignancy undergo a bronchoscopy with biopsy and bronchoalveolar lavage (bal). patients with abnormal ct scan(s) and negative bal for p53 and/or k-ras mutations or normal histology and positive bal for k-ras and/or p53 mutations undergo additional ct scans at 6 months and 1 year. patients with biopsy-proven malignancy after bronchoscopy are referred for definitive treatment. projected accrual: a total of 500 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * women who currently smoke or have smoking history of at least a 30 pack year * pack year is defined by the number of pack(s) of cigarettes per day times the number of years of smoking * no history of prior lung cancer patient characteristics: age: * over 18 performance status: * ecog 0-2 life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified other: * not pregnant or nursing * fertile patients must use effective contraception * no prior cancer within the past 5 years except basal cell or superficial skin cancer or carcinoma in situ of the cervix prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: non-small cell lung cancer small cell lung cancer
impairment-specific and augmented intervention on turning

Conditions: Stroke

Summary: the objective of this study is to investigate the effects of the impairment-specific and augmented intervention based balance and strength training on turning performance in individuals with chronic stroke.


Eligibility criteria:
inclusion criteria: * ≧ 6 months post first-ever stroke with unilateral motor deficits * ≧20 years of age * the ability to walk independently for at least 7 m with or without using walking aids * score ≧ 24 of 30 on the mini-mental state examination exclusion criteria: * unstable medical conditions (e.g., deep vein thrombosis, aspiration pneumonia, or superimposed sepsis) * history of other diseases known to interfere with participation in the study (e.g., heart failure, hemineglect, or diabetic neuropathy)
adverse events in dry needling

Conditions: Muscle Soreness; Headache; Knee Osteoarthritis; Back Pain; Neck Pain; Needle Stick; Shoulder Pain; Hip Osteoarthritis

Summary: the purpose of this prospective cohort survey study is to further explore the incidence of adverse events with dry needling by physical therapists - as well as any differences or similarities between patient-reported vs therapist-reported incidence of aes.

the study design will comprise of an observational study, where practicing clinicians will log data from dry needling sessions and patients will report via online surveys. clinician logs will be collected weekly via an online redcap survey . patients will be instructed to complete an online redcap survey in the event that an adverse event occurs. data will be collected for a period of 4 mo. descriptive statistics will be used to calculate frequencies of various ae's and rates of occurrence per 100 treatments. adverse events will be classified on how frequently they occur, ranging from very common (\>1/10 treatments) to very rare (\<1/10,000 treatments). the investigators will then examine for differences between patient-reported and clinician-reported incidences and also explore for any correlations between adverse events and other various reported factors.

Eligibility criteria:
inclusion criteria: * any patient that receives dry needling as a part of their care by a physical therapist and consents to provide information exclusion criteria: * does not receive dry needling or does not consent to provide information

Keywords: dry needling adverse event physical therapy